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ABSTRACT High pressure liquid chromatography has
enabled quantitative analysis of the in vitro metabolism of
7,12-dimethylbenz[a]anthracene, 7-methyl-12-hydroxymethyl-
benz[alanthracene, 7-hydroxymethyl-12-methylbenz[alanth-
racene, and 7,12-dihydroxymethylbenz[a]anthracene by 3-
methylcholanthrene-induced and control rat liver micro-
somes. The following previously unrecognized metabolites
have been tentatively identified: 5,-dihydro-5,6-dihydroxy-
7-methyl-12-hydroxymethylbenz[alanthracene, 3-hydroxy-
7,12-dihydrodihydroxymethylbenz[alanthracene, 4-hydroxy-7,12-dihydrodihydroxymethylbenz[a]anthracene, and 8,9-di-
hydro-8,9-dihydroxy-7,12-dihydroxymethylbenz[alanthracene.The epoxide hydratase inhibitor 1,2-epoxy-3,3,3-trichloropro-
pane was found to eliminate all dihydrodiol formation and
markedly inhibit the formation of several dimethylbenzan-
thracene metabolites. It is proposed that the tentatively iden-
tified 3-hydroxy and 4-hydroxy derivatives are formed by an
enzymatic mechanism that does not involve epoxides as in-
termediates. The metabolic pathways of 7,12-dimethyl-
benz[a]anthracene in hepatic microsomal enzymes are pro-
posed.
7,12-dimethylbenz[a]anthracene (DMBA) is a potent carcin-
ogen which induces skin tumors in mice (1) and causes
mammary cancer and massive adrenal necrosis in rats (2, 3).
It has been found to induce malignant transformation of in
vitro cell transformation systems (4, 5), and to be mutagenic
in bacteria (6) and mammalian cells (7). The carcinogenic
and mutagenic activities of polycyclic aromatic hydrocar-
bons (PAH) require metabolic activation by mixed-function
oxidases located in the microsomes of mammalian cells (7-
9). The enzyme system is present and inducible in Mvo and
in cells grown in culture (10-13). PAH are metabolized to
phenols, dihydrodiols, quinones, and epoxides (14-23). In
DMBA metabolism, the hydroxylation of the 7-methyl
group is believed to be the key step towards carcinogenesis
in the mammary glands and adrenal necrosis in rats (19,
24-26). Administration of certain aromatic compounds to
rats prior to the feeding of DMBA prevents the induction of
adrenal necrosis by this carcinogen and also inhibits the de-
velopment of mammary cancer (17, 27).
PAH metabolites have been analyzed mainly by thin-
layer chromatography (15, 28, 29), but due to inc'omplete
separation not all the metabolites formed could be examined
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in detail. Recently high-pressure liquid chromatography
(HPLC) has been applied successfully to the analysis of ben-
zo[a]pyrene metabolites (30). This paper describes the quan-
titative analysis of DMBA metabolism with control and 3-
methylcholanthrene (MC)-pretreated rat liver microsomes
by HPLC.
MATERIALS AND METHODS
Materials. [3H]DMBA (specific activity 13 Ci/mmol) and
[14C]DMBA (specific activity 21.2 Ci/mol) were purified on
a silica gel column and HPLC showed them to be 99.8%
pure. The specific activities in methanol solution of [3H]-
and [14C]DMBA used in the experiments were 115.3 and
24.3 Ci/mol, respectively. Synthetic compounds 7-OHM-
12-MBA, 7-M-12-OHMBA, 7,12-di-OHMBA, and DMBA-
cis-5,6-diol were generously provided by Dr. Harry Gelboin
of the National Cancer Institute.
Rat Liver Microsomes and In Vitro Incubations. The
control and MC-induced microsomes of male Sprague-
Dawley rats were prepared according to the procedures of
Kinoshita et al. (18). The incubation mixture contains 50
mM Tris-HCI, pH 7.5, 3 mM MgCl2, 0.56 mM NADPH,
79.2 MiM [3H]DMBA or 88 AM [14C]DMBA, 0.5 mg of pro-
tein per ml of control microsomes or 0.4 mg of protein per
ml of MC-induced microsomes. Unlabeled 7-M-12-OHMBA,
7-OHM-12-MBA, and 7,12-diOHMBA were used at about
50 gM. For the inhibitor experiments, 1,2-epoxy-3,3,3-tri-
chloropropane (TCPO) was used at 93 mM. Incubation, or-
ganic solvent extraction, and sample preparation for HPLC
were carried out similarly as described (30).
High-Pressure Liquid Chromatography. A Dupont
model 830 high-pressure liquid chromatograph fitted with a
1 m Permaphase octadecyltrimethoxysilane (ODS) column
was used. The column was maintained at 50° and 500
pounds/inch2 (3.4 MPa). The column was eluted with a lin-
ear gradient of methanol in water from 20% to 80%.
Five microliters of prepared metabolite sample in metha-
nol were injected with the solvent flow stopped. The eluent
was monitored by ultraviolet absorption at 254 nm. Ten-
drop fractions were collected (12-19 sec intervals) and the
radioactivity was determined. The counting data was con-
verted to pmol by a simple computer program with calibrat-
ed counting efficiency.
RESULTS
Identification of DMBA Metabolites. DMBA metabo-
lites were identified by their chromatographic properties on
thin-layer chromatography and HPLC, and their ultraviolet
and fluorescence spectra, making use of the properties of
known compounds and previous assignments where avail-
able (15, 22, 28, 29, 31).
The chromatographic properties of 7,12-diOHMBA,
DMBA-5,6-diol, 7-OHM-12-MBA, and 7-M-12-OHMBA as-
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FIG. 1. Separation of DMBA and metabolites by high-pressure
liquid chromatography. HPLC was carried out as described in
Materials and Methods. The quantitative aspect of DMBA metab-
olism by control and MC-induced (MC) microsomes is shown in
Table 2.
signed in Fig. 1 were identical to those of the reference com-
pounds. The assigned 8,9-diols of DMBA and its hydroxy-
methyl derivatives have absorption spectra similar to those
determined by Sims (22, 28) and Gentil et al. (31). The 8,9-
diols obtained by incubating 7,12-diOHMBA, 7-OHM-12-
MBA, and 7-M-12-OHMBA separately with microsomes
have identical retention times on HPLC. When 7-OHM-12-
MBA or 7-M-12-OHMBA was used as substrate, the relative
enzyme activities toward 8,9-diol formation (by mono-oxy-
genases and epoxide hydratase) and methyl-hydroxylation
determine the concentration of 7,12-diOHMBA-8,9-diol rel-
ative to that of 7-OHM-12-MBA-8,9-diol (or of 7-M-12-
OHMBA-8,9-diol). It will be shown in Table 2 that the rate
of DMBA-8,9-diol formation is 2.5 to 13 times higher than
that of 7-OHM-12-MBA and 7-M-12-OHMBA, and the rate
of methyl-hydroxylation of the second methyl group ap-
pears to be lower than that of the first methyl group. There-
fore, one would expect that the 8,9-diols obtained from 7-
OHM-12-MBA and 7-M-12-OHMBA are mainly monohy-
droxymethyl derivatives. This is supported by the finding
that the 8,9-diol obtained by incubating 7,12-diOHMBA
Table 1. Fluorescence spectra of phenolic derivatives of
7,12-dimethylbenz [a ] anthracene
Fluor-
Excitation escence
maximum maximum
Compounda (nm)b (nm)b
4-OH-7,12-diOHMBA 285,322,368,402 460
3-OH-7,12-diOHMBA 305, 3709407 470
3-OH-7-OHM-12-MBA 2989 365,405 457
4-OH-7-OHM-12-MBA 290,325,383,409 452
4-OH-7-M-12-OHMBA 2971320,373,402 452
3-OH-7-M-12-OHMBA 305, 367,405 452
3-OH-DMBA 3129 382,410 425,443
4-OH-DMBA 295,325,384,408 425,440
aThe phenolic products were obtained by incubating each of
their corresponding parent compounds with liver microsomes and
were subsequently separated by HPLC.
b Spectra were measured in methanol solution on an Aminco-Bow-
man spectrophotofluorimeter. Highest excitation or fluorescence
maxima are underlined.
with microsomes has ultraviolet absorption and fluorescence
properties distinct from those of the 8,9-diols of 7-OHM-12-
MBA and 7-M-12-OHMBA (unpublished results). The ab-
sorption and fluorescence properties of the assigned 7-M-
12-OHMBA-5,6-diol were similar to those of DMBA-cis-
5,6-diol and DMBA-trans-5,6-diol (31). The phenolic prod-
ucts were extensively studied for their absorption and fluo-
rescence properties in both methanol and 1 N NaOH. The
compound assigned as 4-OH-DMBA in Fig. 1 has similar ab-
sorption spectrum to the synthetic standard (31). The ab-
sorption spectrum of 4-OH-DMBA in methanol has a char-
acteristic absorption maximum at 320 nm. This absorption
characteristic prevails in all the 4-hydroxy derivatives and is
absent in all the 3-hydroxy derivatives assigned in Fig. 1. As
shown in Table 1, the absorption characteristics were reflect-
ed in their fluorescence properties. All the assigned 4-hy-
droxy derivatives have an excitation maximum at around
320 nm which is absent in the assigned 3-hydroxy deriva-
tives. The phenolic characters of the compounds in Table 1
Table 2. DMBA metabolism analyzed by high-pressure
liquid chromatography
Retention nmol/mg proteina
time MC-
Metabolite (min) induced Control
7,12-diOHMBA-8,9-diolb 3.2 4.7 2.4
7-M-12-OHMBA-5.6-diolc 4.7 10.3 3.4
Unknown no. id 6.0 - -
3-OH-7,12-diOHMBA 6.6 - 0.25
DMBA-8,9-diol 7.4 24.2 2.4
7,12-diOHMBA 10.2 1.5 1.2
Unknown no. 2e 11.2 - -
DMBA-5,6-diole 12.7
3-OH-7-OHM-12-MBA 14.9 1.1 -
Unknown no. 3f 16.3 0.15 -
4-OH-7-OHM-12-MBA 17.5 1.2 0.8
Unknown no. 4f 18.2 - -
4-OH-7-M-12-OHMBA 19.2 - 0.3
3-OH-7-M-12-OHMBAg 21.5 - -
7-OHM-12-MBA 24.5 9.6 4.9
7-M-12-OHMBA 26.6 1.9 3.0
3-OH-DMBA 30.9 2.2 0.5
4-OH-DMBA 32.2 1.0 0.3
Unknown no. Sf 33.6 - 0.3
DMBA 39.5 - -
Total metabolites 57.9 19.8
% Metabolized 29 12
a Nanomoles of metabolite detected per ml of incubation mixture
per mg of protein microsomes for a 30 min incubation at 37°. Con-
trol and MC-induced microsomes were used at 0.5 and 0.4 mg of
protein per ml, respectively. Errors of the determined values are
estimated to be about 7%.
bThis chromatographic peak may contain 7-M-12-OHMBA-8,9-
diol and 7-OHM-12-MBA-8,9-diol.
c A small amount of 4-OH-7,12-diOHMBA is present in this
chromatographic peak.
d Detected as metabolite when either 7-OHM-12-MBA or 7-M-12-
OHMBA was used as substrate in the incubation.
e Detected as minor metabolites when DMBA is incubated with
MC-induced microsomes in a 30 ml incubation mixture (this is
indicated in Fig. 1).
f Chromatographic peaks were unidentified due to small quantity
present and close association with neighboring metabolites.
g Detected as a metabolite when 7-M-12-OHMBA was used as
substrate in the incubation.
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Table 3. Effect of TCPO on DMBA metabolism
nmol/mg of proteina
% In-
Metabolite - TCPO + TCPO hibition
7,12-diOHMBA-8,9-diolb 4.7 0 100
4-OH-7,12-diOHMBA - 0.2 -
7-M-12-OHMBA-5,6-diol 10.30 0 100
3-OH-7,12-diOHMBA - 0.09 -
DMBA-8,9-diol 24.2 0 100
7,12-diOHMBA 1.5 0.14 75
3-OH-7-OHM-12-MBA 1.1 0 100
Unknown no. 3 0.15 0.14 6
4-OH-7-OHM-12-MBA 1.2 0 100
Unknown no. 4 - 0.15 -
4-OH-7-M-12-OHMBA - 0.2 -
7-OHM-12-MBA 9.6 1.6 83
7-M-12-OHMBA 1.9 0.5 74
3-OH-DMBA 2.2 0.3 86
4-OH-DMBA 1.0 0.2 80
Total Metabolites 57.9 3.8 94
% Metabolized 29 1.7 94
a MC-induced microsomes were each used at 0.4 mg of protein per
ml.
bThis chromatographic peak may contain 7-M-12-OHMBA-8,9-
diol and 7-OHM-12-MBA-8,9-diol.
were ascertained by their red-shifts of fluorescence maxima
in alkaline solution (unpublished results). Although the spec-
trophotofluorimetric and spectrophotometric properties of
the compounds were determined, it should be pointed out
that the assignments in Fig. 1 and Table 1 are tentative for
those lacking reference standards.
Metabolism of DMBA by Control and MC-Induced Mi-
crosomes. Fig. 1 shows the HPLC separation of DMBA and
metabolites produced by incubating DMBA with control
and MC-induced microsomes. The quantities of each metab-
olite are listed in Table 2. The detected DMBA metabolites
can be divided into three classes: (1) methyl-hydroxylated
derivatives (e.g., 7-M-12-OHMBA, 7-OHM-12-MBA, and
7,12-diOHMBA), (2) phenolic derivatives of DMBA and its
methyl-hydroxylated derivatives, and (3) dihydrodihydroxy
derivatives of DMBA and its methyl-hydroxylated deriva-
tives. Classes 2 and 3 are commonly called ring-hydroxyl-
ated derivatives. The activity ratios of Table 2 demonstrate
that MC-induced microsomes stimulate the formation of all
metabolites with the exceptions of 7-M-12-OHMBA and 4-
OH-7-M-12-OHMBA.
MC-induced microsomes yield twice as much 7-OHM-
12-MBA as the control microsomes. This stimulatory effect is
reproducible. The results presented here agree qualitatively
with the data of Sims (28) with respect to increased forma-
tion of 7-OHM-12-MBA and decreased formation of 7-M-
12-OHMBA with MC-induced rat liver homogenates com-
pared with control homogenates. However, this finding is in
disagreement with those of Boyland et al. (25), and Jellinck
et al. (24), who found a decreased level of 7-OHM-12-MBA
with MC-induced microsomes.
Metabolism of DMBA by MC-Induced Microsomes in
the Presence of TCPO. The epoxide hydratase inhibitor
TCPO (32) is known to inhibit effectively the formation of
all benzo[alpyrene-diols and other metabolites (30). As
shown in Table 3, TCPO has a similar effect on DMBA me-
tabolism. The total metabolism of DMBA is reduced by 94%
Table 4. Metabolism of 7-M-12-OHMBA, 7-OHM-12-MBA,
and 7,12-diOHMBA by MC-induced microsomes
Substratea
7-M-12- 7-OHM- 7,12-
Metabolite OHMBA 12-BA diOHMBA
7-OHM-1 2-MBA-8,9-diol +
7-M-12-OHMBA-8,9-diol +
7,12-diOHMBA-8,9-diol x x +
3-OH-7,1 2-diOHMBA +
7-M-12-OHMBA-5,6-diol +
Unknown no. lb + +
4-OH-7,12-diOHMBA +
7,12-diOHMBA + + +
4-OH-7-OHM-1 2-MBA +
3-OH-7-OHM-1 2-MBA +
3-OH-7-M-12-OHMBA +
4-OH-7-M-12-OHMBA +
a The incubations were carried out as described in Materials and
Methods. Positive sign indicates the presence of that metabolite.
The x indicates the presence of 7,12-diOHMBA-8,9-diol, but the
amount relative to the monohydroxymethyl derivative is esti-
mated to be small (see text). Some minor chromatographic peaks
less polar (with longer retention times on HPLC) than the parent
compounds were detected. Their identities are unknown.
b This metabolite had an absorption maximum at 268 nm and a
shoulder at 260 nm, fluorescence maximum at 465 nm with ex-
citation at 375 nm.
in the presence of 93 mM TCPO. Formation of phenolic and
hydroxymethyl derivatives was drastically inhibited (except
phenols of 7-OHM-12-MBA). No dihydrodihydroxy deriva-
tives (presumably formed via epoxides) are produced. Be-
cause of the absence of dihydrodihydroxy derivatives, the
phenolic derivatives of 7,12-diOHMBA are present as dis-
tinctive chromatographic peaks on HPLG.
Metabolism of 7-M-12-OHMBA, 7-OHM-12-MBA, and
7,12-diOHMBA by MC-Induced Microsomes. The metabo-
lites detected and characterized are shown in Table 4. The
quantitative metabolism could not be determined because
unlabeled parent compounds were used. The metabolites of
7-OHM-12-MBA were produced in approximately equal
quantity, estimated by their absorbances (peak area at 254
nm) on the chromatogram. Unknown no. 1 and 7-OHM-12-
MBA-8,9-diol were totally absent when the incubation was
carried out in the presence of TCPO.
About 80% of the metabolites formed by incubating 7-M-
12-OHMBA are 7-M-12-OHMBA-5,6-diol. Formation of this
K-region diol (K-region refers to the "electron rich" region)
was totally inhibited by TCPO; it is also a major metabolite
when DMBA is used as substrate (Table 2). Two phenolic
and one dihydrodihydroxy derivatives were detected as me-
tabolites of 7,12-diOHMBA.
DISCUSSION
The efficient separation of DMBA metabolites by HPLC has
provided a more quantitative analysis and a better under-
standing of the metabolic pathways of DMBA in the in vitro
system. It has been reported that metabolites formed in vitro
are mainly monohydroxymethyl derivatives of DMBA (14).
We have shown that (1) the phenolic and dihydrodihydroxy
derivatives of DMBA, (2) 7-OHM-12-MBA and 7-M-12-
OHMBA, and (3) the phenolic and dihydrodihydroxy deriv-
atives of 7-OHM-12-MBA and 7-M-12-OHMBA are formed
in comparable quantities. A dihydroxymethyl derivative is
also formed in a significant amount.
Biochemistry: Yang and Dower
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horizontal paths indicate ring-hydroxylation. Experimental evidence, (- ); partial evidence (ref. 17), ( . -); proposed additional
pathways, ( .------).
The detection of a K-region diol, 7-M-12-OHMBA-5,6-
diol, is of special interest. Sims (Table 1 of ref. 22) character-
ized this metabolite as 7-M-12-OHMBA-8,9-diol which was
thought to be the major metabolite of 7-M-12-OHMBA. It
has been suggested that K-region epoxides are active inter-
mediates responsible for the carcinogenic activities of PAH
(5, 33-36). Epoxides are found to be active in inducing ma-
lignant cell transformations (5, 34, 36, 37) and are mutagen-
ic (36,38,39). The K-region epoxide of 7-M-12-OHMBA has
not been tested for malignant and mutagenic activities.
However, it was shown that 7-M-12-OHMBA is inactive in
inducing adrenal necrosis in rats and mice, and mammary
cancer in rats (25).
Some phenolic derivatives of DMBA, 7-OHM-12-MBA,
and 7-M-12-OHMBA have been tentatively identified (14,
15, 25). Metabolites that derive from further metabolism of
7,12-diOHMBA have not been reported. The discovery of
metabolites derived from 7,12-diOHMBA provides evidence
that 7,12-diOHMBA is not the end product of microsomal
oxidations. Monohydroxymethyl derivatives can be first hy-
droxylated on the second methyl group, and the dihydroxy-
methyl derivative can be further hydroxylated at the ring
positions to form dihydrodihydroxy and phenolic deriva-
tives. Boyland et al. (14) have found that 7-OHM-12-MBA is
more active in inducing adrenal necrosis and mammary can-
cer in rats. Flesher et al. (40) have shown that derivatives ca-
pable of being converted to 7-OHM-12-MBA are potent car-
cinogens. The dihydroxymethyl derivative was found inac-
tive in inducing palpable tumors in rats (40). Some ring-hy-
droxylated derivatives of DMBA and 7-OHM-12-MBA were
found inactive- in either inducing tumors (40) or inducing
malignant cell transformation (5). Therefore, it appears that
metabolism of 7,12-diOHMBA is a route that leads to detoxi-
fication.
Pretreatment of rats with some aromatic compounds pro-
tects the animals from adrenal necrosis (2, 3, 11, 15, 26, 27).
It has been suggested that induced hepatic microsomal en-
zymes decrease the effective concentration of 7-OHM-12-
MBA, which is believed to be the adrenocorticolytic agent
that causes adrenal damage in rats (25). Our results further
confirm the earlier reports (15, 24, 29) that MC-induced mi-
crosomal enzymes metabolize DMBA more effectively at the
ring positions and the rate of further metabolism of mo-
nohydroxymethyl derivatives is accelerated. However, our
results show that the net concentration of 7-OHM-12-MBA
produced with MC-induced microsomes is two times higher
than that produced with control microsomes under identical
conditions. Therefore, the increased ring-hydroxylation is
not at the expense of hydroxylation of the methyl groups as
has been suggested by earlier reports (15, 28). Wheatley and
Sims (26) have proposed that 7-OHM-12-MBA requires fur-
ther metabolism or conjugation in the liver to exert its ne-
crotic effect in adrenal cortex. Recently, 7-OHM-12-MBA-
5,6-oxide was shown to be inactive in inducing adrenal ne-
crosis in Sprague-Dawley-rats (17). Further investigation is
clearly needed before 7-OHM-12-MBA can be implicated as
the ultimate metabolite that causes adrenal necrosis and
mammary cancer in experimental animals.
A number of K-region epoxides have been shown to be in-
termediates in the in vitro metabolism of carcinogenic PAH
(16, 17, 20, 41, 42). Epoxides are shown to: (1) bind to cellu-
lar macromolecules (33), (2) undergo nonenzymatic rear-
rangement to phenolic derivatives (42-44),.(3) form a gluta-
thione conjugate in a reaction catalyzed by the cytoplasmic
Proc. Nat. Acad. Sci. USA 72 (1975)
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S-epoxide transferase (32), and (4) form dihydrodiols in
reactions catalyzed by the microsomal epoxide hydratase
(32). Although NIH shift mechanism is shown to be involved
in the nonenzymatic rearrangement of epoxides to phenolic
derivatives (42-44), there have been examples of direct en-
zymatic formation of a phenol (42). In the in vitro metabo-
lism of benzo[a]pyrene (BP), there has been direct evidence
for the presence of BP-4,5-oxide (17) and indirect evidence
for the presence of BP-7,8-oxide and BP-9,10-oxide (18, 30).
However, there has been no indication of the formation of
BP-2,3-oxide (30). 3,4-oxides of DMBA, 7-OHM-12-MBA,
7-M-12-OHMBA, and 7,12-diOHMBA have not been de-
tected, either directly by the detection of the epoxide itself
or indirectly by the detection of its dihydrodiol. Yet 3-hy-
droxy-BP (30), 3-hydroxy and 4-hydroxy derivatives of
DMBA, 7-M-12-OHMBA, 7-OHM-12-MBA, and 7,12-
diOHMBA are formed even in the presence of TCPO,
which inhibited the formation of all dihydrodiols. It is prob-
able that 3,4-oxides formed are very unstable and quickly
rearranged to 3- and 4-hydroxy derivatives. However, an al-
ternative explanation is that the phenol formation is via an
unknown enzymatic mechanism which does not involve ep-
oxides as intermediates. If this were the case, there exists in
the microsomal complex a "ring-hydroxylase" which cata-
lyzes the formation of phenolic derivatives from DMBA and
its hydroxymethyl derivatives. One can also speculate, for
reasons of enzyme-substrate specificity, that the enzymes
responsible for the methyl-hydroxylation and phenol forma-
tion are different entities in a microsomal multi-enzyme
complex. If this is indeed the case, there exists in the micro-
somal complex a "methyl-hydroxylase" that catalyzes the
formation of hydroxymethyl derivatives from DMBA and its
ring-hydroxylated derivatives (including phenols and dihy-
drodiols). This hypothesis is indicated in Fig. 2, the proposed
metabolic pathways by microsomal enzymes. The well-es-
tablished nonenzymatic rearrangement of epoxides to phe-
nols (42-44) is not shown in Fig. 2. Keysell et al. have re-
ported that DMBA-cis-5,6-diol is metabolized to 7-OHM-
12-MBA-cis-5,6-diol by rat liver microsomes. This is the only
known case where a ring-hydroxylated derivative can be
further methyl-hydroxylated. The action of "ring-hydroxyl-
ase" is exemplified by the formation of phenolic derivatives
from DMBA, 7-OHM-12-MBA, 7-M,12-OHMBA, and 7,12-
diOHMBA. However, this concept requires further investi-
gation to substantiate the existence of a "methyl-hydroxyl-
ase" and a "ring-hydroxylase" as components of microsomal
mixed-function oxidases.
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